Edition:
United Kingdom

Prothena Corporation PLC (PRTA.OQ)

PRTA.OQ on NASDAQ Stock Exchange Global Select Market

9.49USD
24 May 2019
Change (% chg)

$0.55 (+6.15%)
Prev Close
$8.94
Open
$9.00
Day's High
$9.60
Day's Low
$9.00
Volume
141,257
Avg. Vol
113,576
52-wk High
$15.91
52-wk Low
$8.66

Latest Key Developments (Source: Significant Developments)

Prothena Corporation PLC Files For Mixed Shelf Of Upto $150 Million
Wednesday, 22 May 2019 

May 22 (Reuters) - Prothena Corporation PLC ::PROTHENA CORPORATION PLC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Prothena Q1 Loss Per Share $0.52
Tuesday, 7 May 2019 

May 7 (Reuters) - Prothena Corporation PLC ::PROTHENA REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES RESEARCH AND DEVELOPMENT UPDATE.Q1 LOSS PER SHARE $0.52.Q1 EARNINGS PER SHARE ESTIMATE $-0.62 -- REFINITIV IBES DATA.AS OF MARCH 31, 2019, PROTHENA HAD $414.2 MILLION IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH AND NO DEBT..UPDATING ITS FULL YEAR 2019 NET CASH BURN FROM OPERATING AND INVESTING ACTIVITIES, AND EXPECTS IT TO BE $57-65 MILLION.  Full Article

Prothena Corporation Q1 Loss Per Share $0.52
Tuesday, 7 May 2019 

May 7 (Reuters) - Prothena Corporation PLC ::PROTHENA REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES RESEARCH AND DEVELOPMENT UPDATE.Q1 LOSS PER SHARE $0.52.Q1 EARNINGS PER SHARE ESTIMATE $-0.62 -- REFINITIV IBES DATA.UPDATING ITS FULL YEAR 2019 NET CASH BURN FROM OPERATING AND INVESTING ACTIVITIES TO BE $57-65 MILLION.EXPECTS TO END YEAR WITH APPROXIMATELY $371 MILLION IN CASH.  Full Article

Prothena Reports Results From The Phase 3 VITAL Amyloidosis Study Of NEOD001 In AL Amyloidosis
Thursday, 18 Apr 2019 

April 18 (Reuters) - Prothena Corporation PLC ::PROTHENA REPORTS RESULTS FROM THE PHASE 3 VITAL AMYLOIDOSIS STUDY OF NEOD001 (BIRTAMIMAB) IN AL AMYLOIDOSIS.PROTHENA CORPORATION PLC - RESULTS FROM FINAL ANALYSIS OF COMPOSITE PRIMARY ENDPOINT WERE CONSISTENT WITH FUTILITY ANALYSIS REPORTED IN APRIL 2018.PROTHENA CORPORATION PLC - EXPLORING POTENTIAL BUSINESS DEVELOPMENT OPPORTUNITIES TO ADVANCE NEOD001.PROTHENA CORPORATION PLC - RESULTS FROM POST HOC ANALYSES REVEALED A POTENTIAL SURVIVAL BENEFIT WITH NEOD001.PROTHENA CORPORATION PLC - EXPLORING POTENTIAL BUSINESS DEVELOPMENT OPPORTUNITIES TO ADVANCE NEOD001.PROTHENA CORPORATION PLC - EXPLORING POTENTIAL BUSINESS DEVELOPMENT OPPORTUNITIES THAT COULD RESULT IN FURTHER CLINICAL INVESTIGATION OF NEOD001.PROTHENA CORPORATION PLC - NEOD001 AND CONTROL ARMS HAD SIMILAR FREQUENCIES OF TREATMENT EMERGENT ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS.  Full Article

Prothena Q3 Loss Per Share $0.62
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Prothena Corporation PLC ::PROTHENA REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES RESEARCH AND DEVELOPMENT UPDATE.Q3 LOSS PER SHARE $0.62.Q3 EARNINGS PER SHARE VIEW $-0.98 -- THOMSON REUTERS I/B/E/S.QUARTER-END CASH AND RESTRICTED CASH POSITION OF $455.6 MILLION.CONTINUES TO EXPECT ITS 2018 NET CASH BURN FROM OPERATING AND INVESTING ACTIVITIES TO BE $40 TO $50 MILLION.PROTHENA - ESTIMATED 2018 NET CASH BURN FROM OPERATING AND INVESTING ACTIVITIES IS PRIMARILY DRIVEN BY AN ESTIMATED NET LOSS OF $170 TO $185 MILLION.  Full Article

Prothena Q3 Loss Per Share $0.62
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Prothena Corporation PLC ::PROTHENA REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES RESEARCH AND DEVELOPMENT UPDATE.Q3 LOSS PER SHARE $0.62.Q3 EARNINGS PER SHARE VIEW $-0.98 -- THOMSON REUTERS I/B/E/S.QTRLY TOTAL REVENUE $255,000 VERSUS $219,000.Q3 REVENUE VIEW $802430.00 -- THOMSON REUTERS I/B/E/S.CONTINUES TO EXPECT ITS 2018 NET CASH BURN FROM OPERATING AND INVESTING ACTIVITIES TO BE $40 TO $50 MILLION.  Full Article

Prothena Announces Global Neuroscience Research & Development Collaboration With Celgene
Tuesday, 20 Mar 2018 

March 20 (Reuters) - Prothena Corporation Plc ::PROTHENA ANNOUNCES GLOBAL NEUROSCIENCE RESEARCH & DEVELOPMENT COLLABORATION WITH CELGENE FOR NOVEL THERAPIES FOR PATIENTS WITH NEURODEGENERATIVE DISEASES.PROTHENA CORPORATION - PROTHENA TO RECEIVE A $100 MILLION UPFRONT PAYMENT AND A $50 MILLION EQUITY INVESTMENT BY CELGENE.PROTHENA CORPORATION- COLLABORATION INCLUDES POTENTIAL LICENSE PAYMENTS, MILESTONES, PLUS ADDITIONAL ROYALTIES ON SALES FROM LICENSED PROGRAMS FOR CO.PROTHENA CORPORATION PLC - CELGENE WILL SUBSCRIBE TO ABOUT 1.2 MILLION OF PROTHENA'S ORDINARY SHARES AT $42.57 PER SHARE.  Full Article

Prothena Corp Files For Potential Stock Shelf Offering
Monday, 26 Feb 2018 

Feb 26 (Reuters) - Prothena Corporation Plc ::PROTHENA CORPORATION PLC FILES FOR POTENTIAL STOCK SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Prothena Q4 Loss Per Share $1.24
Wednesday, 14 Feb 2018 

Feb 14 (Reuters) - Prothena Corporation Plc ::PROTHENA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS, AND PROVIDES FINANCIAL GUIDANCE AND RESEARCH AND DEVELOPMENT UPDATE.Q4 LOSS PER SHARE $1.24.Q4 REVENUE $200,000.AS OF DECEMBER 31, 2017, PROTHENA HAD $421.7 MILLION IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH AND NO DEBT.EXPECTS THE FULL YEAR 2018 NET CASH BURN FROM OPERATING AND INVESTING ACTIVITIES TO BE $175 TO $230 MILLION.Q4 EARNINGS PER SHARE VIEW $-1.48, REVENUE VIEW $237600.00 -- THOMSON REUTERS I/B/E/S.  Full Article

Prothena reports Q3 loss per share $1.37
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Prothena Corporation Plc ::Prothena reports third quarter 2017 financial results and provides research and development update.Q3 loss per share $1.37.Q3 revenue $200,000.Q3 revenue view $251,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-1.39 -- Thomson Reuters I/B/E/S.  Full Article